Skip to content

Effects of Viscous Fibre Containing Foods on Satiety (Gel Form)

Effects of High-Fibre, Low-Energy Density Viscous Gel Meals on Satiety, Appetite Regulation and Subsequent Food Intake in Healthy Individuals

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02134938
Enrollment
20
Registered
2014-05-09
Start date
2013-07-31
Completion date
Unknown
Last updated
2014-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The purpose of this study is to assess whether low caloric, low energy density, konjac food products are effective in appetite regulation when administered as caloric replacements. It is hypothesized that replacement of typical, balanced, vegetarian meals with konjac food products will have comparable satiety scores, decreased postprandial glucose response, and will not significantly affect subsequent food intake.

Interventions

DIETARY_SUPPLEMENTKonjac Glucomannan

Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy, non-smoking males and females * Aged 18-70 years * BMI between 18 - 29.9 kg/m² * Non-dieters (1-10 score on Stunkard Eating Inventory)

Exclusion criteria

* Known reported history of liver or kidney disease, diabetes, hypertension, stroke or myocardial infarctions, thyroid disease, Celiac disease/gastrointestinal disease, or AIDS * Weight change of +/- 3kg in the last 2 months * Alcohol intake \>2 drinks/day * Inability to consume KJM-G meals * Any condition which might jeopardize the health and safety of the subject or study personnel, or adversely affect the study results * Non-compliance with experimental procedures or safety guidelines

Design outcomes

Primary

MeasureTime frameDescription
Subjective Satiety12 hours for each of the 3 study visits.Subjects will record their subjective satiety ratings using a 100 mm visual analogue scale and these ratings will be combined into a total subjective appetite score using the formula (Q1+Q2+(100-Q3)+Q4)/4.

Secondary

MeasureTime frameDescription
Height and WeightTaken once at the beginning of each of the 3 clinical visits.
Blood SamplesOne sample taken immediately prior to (0min) eating each meal (Breakfast, Lunch, Snack and Dinner) and at 30, 60, 90 and 120 min after eating the Breakfast and Lunch meals for each of the 3 study visits (total of 12 blood samples per study visit).Capillary blood samples will be collected in anticoagulant containing tubes stored at -20°C and analyzed by trained personnel for plasma glucose concentration using the glucose oxidase method by YSI 2300 STAT Plus within 48 hours.
Ambulatory Blood PressureMeasured at the beginning of each of the 3 study visits and every 30 minutes thereafter until 10:00pm the same day.
Food Craving RatingRated immediately prior (0min) to eating each meal (Breakfast, Lunch, Snack and Dinner) for each of the 3 study visits.Subjects will record their subjective food craving ratings, if any, prior to each meal, using a 100mm visual analogue scale.
Subsequent Food IntakeRecorded from the 12th to the 24th hour after beginning the first meal (Breakfast at 0min) for each of the 3 study visits.Subjects will record their subsequent food intake from 12h to 24h post first meal. Food record will be analyzed with The Nutrition Food Processor (ESHA) and data will be tabulated and included as part of the cumulative daily food intake.
Palatability ScoresMeasured immediately after eating and finishing (<15min after the first bite) each meal (Breakfast, Lunch, Snack and Dinner) for each of the 3 study visits.

Countries

Canada

Contacts

Primary ContactRodney Au-Yeung, BSc
auyeungf@smh.ca(416) 864-6060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026